Fig. 5: Bortezomib inhibits the proliferation of NSCLC cells by cell cycle arrest.

A The picture showed the changes in cell morphology and number of different NSCLC cells treated with bortezomib (scale bar =100 μm). B The line chart showed the cell growth rates of bortezomib-treated group and control group cells in seven types of NSCLC cells. ****P < 0.0001. C The number of cell clones in the bortezomib-treated group and the corresponding control group was counted by clone formation experiments. D Histogram showed the percentages of seven types of NSCLC cells in different phase of cell cycle (G0/G1, S and G2/M) after treated with bortezomib. Bor: bortezomib, *P < 0.05, **P < 0.01. E, F The protein expression of cell cycle related molecules in A549, H1299, H358, PC9, PC9OR, H3122 and H3122LR cells under different concentrations of bortezomib. The IC₅₀ of A549 was 3.38 nM and the IC₂₅ was 2.88 nM; the IC₅₀ of H1299 was 3.1 nM and the IC₂₅ was 2.76 nM; the IC₅₀ of H358 was 3.12 nM and the IC₂₅ was 2.72 nM. The IC₅₀ of PC9 was 7.45 nM and the IC₂₅ was 5.83 nM; the IC₅₀ of PC9OR was 8.72 nM and the IC₂₅ was 6.24 nM; the IC₅₀ of H3122 was 4.52 nM and the IC₂₅ was 3.86 nM; and the IC₅₀ of H3122LR was 6.59 nM and the IC₂₅ was 4.75 nM.